Grape King Bio Ltd (TPE:1707)

Market Cap	16.07B -18.7%
Revenue (ttm)	10.28B -7.1%
Net Income	1.19B -15.2%
EPS	8.41 -10.3%
Shares Out	148.14M
PE Ratio	12.90
Forward PE	n/a
Dividend	6.00 (5.48%)
Ex-Dividend Date	Jun 17, 2026

Volume	313,344
Average Volume	240,607
Open	108.50
Previous Close	108.50
Day's Range	107.00 - 108.50
52-Week Range	107.00 - 138.00
Beta	0.26
RSI	17.47
Earnings Date	May 20, 2026

About Grape King Bio

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company provides health products and supplements; and microbial fermentation for mushroom mycelium, probiotics, and enzymes. It also offers functional ingredients for intestinal care, immunity regulatio...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1969
• Employees: 501
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1707

Financial Performance

In 2025, Grape King Bio's revenue was 10.25 billion, a decrease of -8.14% compared to the previous year's 11.16 billion. Earnings were 1.22 billion, a decrease of -15.88%.